The Pathology Core is responsible (1) for accrual of residual material not required for diagnosis from human melanomas and nevi for use in the Projects;(2) for the provision of expert pathological assistance in the interpretation of histological data to the Projects;and (3) for the development of immunohistochemical, in situ hybridization, microdissection and mRNA amplification methods to enable the identification of antigens or mRNAs in archival and freshly-isolated tissues. Many antibodies and/or probes of relevance to the projects in this proposal are available with reqactivity in fixed or frozen tissue. The Core has access to a very large collection of human tissue biopsies including thousands of pigmented lesions in the affiliated laboratories of Surgical Pathology (23,000 accessions/year) and of dermatopathology (50,000). The database of the Pigmented Lesion Group including glass slides of virtually all of the >4000 cases of primary accrued by the Group since 1972 is available to the Core for analysis of attributes to be used in model-building, and for selection of blocks to be retrieved from the permanent archives of our own laboratories and of contributing laboratories. Expertise in all aspects of the pathological diagnosis and classification of melanocytic neoplasms is provided to the projects on a continuing basis.
| Perego, M; Maurer, M; Wang, J X et al. (2018) A slow-cycling subpopulation of melanoma cells with highly invasive properties. Oncogene 37:302-312 |
| Heppt, Markus V; Wang, Joshua X; Hristova, Denitsa M et al. (2018) MSX1-Induced Neural Crest-Like Reprogramming Promotes Melanoma Progression. J Invest Dermatol 138:141-149 |
| Cañadas, Israel; Thummalapalli, Rohit; Kim, Jong Wook et al. (2018) Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses. Nat Med 24:1143-1150 |
| Jenkins, Russell W; Aref, Amir R; Lizotte, Patrick H et al. (2018) Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. Cancer Discov 8:196-215 |
| Liu, Shujing; Zhang, Gao; Guo, Jianping et al. (2018) Loss of Phd2 cooperates with BRAFV600E to drive melanomagenesis. Nat Commun 9:5426 |
| Reyes-Uribe, Patricia; Adrianzen-Ruesta, Maria Paz; Deng, Zhong et al. (2018) Exploiting TERT dependency as a therapeutic strategy for NRAS-mutant melanoma. Oncogene 37:4058-4072 |
| Chen, Gang; Huang, Alexander C; Zhang, Wei et al. (2018) Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature 560:382-386 |
| Taylor, Laura A; Abraham, Ronnie M; Tahirovic, Emin et al. (2017) High ALDH1 expression correlates with better prognosis in tumorigenic malignant melanoma. Mod Pathol 30:634-639 |
| Lu, Hezhe; Liu, Shujing; Zhang, Gao et al. (2017) PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas. Nature 550:133-136 |
| Vitiello, Marianna; Tuccoli, Andrea; D'Aurizio, Romina et al. (2017) Context-dependent miR-204 and miR-211 affect the biological properties of amelanotic and melanotic melanoma cells. Oncotarget 8:25395-25417 |
Showing the most recent 10 out of 382 publications
